David D. Dingli

Hematology
200 1st St SW
Rochester, MN 55905

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 440 publications

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Journal: American journal of hematology
Published: May 30, 2026

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents.

Journal: American journal of hematology
Published: May 12, 2026

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Journal: Research square
Published: April 17, 2026

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia
Published: April 14, 2026

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement.

Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement.

Journal: Blood advances
Published: April 07, 2026

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Journal: Blood advances
Published: April 07, 2026

Self-Reported Geriatric Impairments and Treatment Toxicity in Older Patients with Multiple Myeloma-A Single Center Prospective Study.

Self-Reported Geriatric Impairments and Treatment Toxicity in Older Patients with Multiple Myeloma-A Single Center Prospective Study.

Journal: Blood advances
Published: March 31, 2026

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

Journal: American journal of hematology
Published: March 31, 2026

Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma.

Biomarkers of Cellular Senescence and their Association with Frailty, Clinical Outcomes, and Survival in Multiple Myeloma.

Journal: Research square
Published: March 27, 2026

High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.

High prevalence of iron deficiency among daratumumab-treated newly diagnosed multiple myeloma patients.

Journal: British journal of haematology
Published: March 23, 2026

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

Journal: American journal of hematology
Published: March 17, 2026

Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma.

Predictors of post-transplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma.

Journal: Blood advances
Published: March 06, 2026
Showing 1-12 of 440

Last Updated: 09/26/2026